Literature DB >> 28529893

Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies.

Charles B Simone1, Abigail T Berman2, Salma K Jabbour3.   

Abstract

Entities:  

Year:  2017        PMID： 28529893      PMCID： PMC5420536          DOI： 10.21037/tlcr.2017.04.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  27 in total

1.  Modern radiotherapy using image guidance for unresectable non-small cell lung cancer can improve outcomes in patients treated with chemoradiation therapy.

Authors:  Matthew P Deek; Sinae Kim; Ning Yue; Rekha Baby; Inaya Ahmed; Wei Zou; John Langenfeld; Joseph Aisner; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 2.  Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Joe Y Chang; Salma K Jabbour; Dirk De Ruysscher; Steven E Schild; Charles B Simone; Ramesh Rengan; Steven Feigenberg; Atif J Khan; Noah C Choi; Jeffrey D Bradley; Xiaorong R Zhu; Antony J Lomax; Bradford S Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-01-23       Impact factor: 7.038

3.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

Review 4.  Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.

Authors:  Charles B Simone; Stuart H Burri; John H Heinzerling
Journal:  Transl Lung Cancer Res       Date:  2015-10

5.  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.

Authors:  Amit A Lugade; James P Moran; Scott A Gerber; Robert C Rose; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

Review 6.  The use of proton therapy in the treatment of lung cancers.

Authors:  Charles B Simone; Ramesh Rengan
Journal:  Cancer J       Date:  2014 Nov-Dec       Impact factor: 3.360

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Martin Reck; Alexander Luft; Aleksandra Szczesna; Libor Havel; Sang-We Kim; Wallace Akerley; Maria Catherine Pietanza; Yi-Long Wu; Christoph Zielinski; Michael Thomas; Enriqueta Felip; Kathryn Gold; Leora Horn; Joachim Aerts; Kazuhiko Nakagawa; Paul Lorigan; Anne Pieters; Teresa Kong Sanchez; Justin Fairchild; David Spigel
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

Review 9.  Risk factors and management of oligometastatic non-small cell lung cancer.

Authors:  Akshar N Patel; Charles B Simone; Salma K Jabbour
Journal:  Ther Adv Respir Dis       Date:  2016-04-08       Impact factor: 4.031

10.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245
View more
  5 in total

1.  Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

Authors:  Salma K Jabbour; Abigail T Berman; Roy H Decker; Yong Lin; Steven J Feigenberg; Scott N Gettinger; Charu Aggarwal; Corey J Langer; Charles B Simone; Jeffrey D Bradley; Joseph Aisner; Jyoti Malhotra
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

2.  Advances in radiation therapy for thoracic malignancies.

Authors:  Charles B Simone; Shahed N Badiyan; Pranshu Mohindra
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 3.  Proton therapy for small cell lung cancer.

Authors:  Vivek Verma; J Isabelle Choi; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 4.  The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature.

Authors:  Ioanna Tsiouprou; Athanasios Zaharias; Dionisios Spyratos
Journal:  Can Respir J       Date:  2019-11-03       Impact factor: 2.409

Review 5.  The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review.

Authors:  John H Heinzerling; Kathryn F Mileham; Charles B Simone
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 0.496
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.